Xeris Biopharma Holdings Inc
XERS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$2.89
66.7% downside
Current Fair Value
66.7% downsideOvervalued by 66.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.85 |
| Outstanding Shares | 172,823,455 |
Return
| Return on Equity | 176.34% |
|---|---|
| Return on Assets | -4.17% |
| Return on Invested Capital | 0.71% |
Valuation & Multiples
| P/E Ratio | -89.6 |
|---|---|
| PEG | -5.92 |
| Price to Sales | 8.68 |
| Price to Book Ratio | -8.68 |
| Enterprise Value to Revenue | 4.98 |
| Enterprise Value to EBIT | 1060.79 |
| Enterprise Value to Net Income | -98 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | -29.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$90.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$101.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6435▼ 5.11% |
|---|---|
| Total Calls | 875,400▲ 6.68% |
| Total Puts | 563,300▼ 1.18% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 65.09%▲ 1.70% |
|---|---|
| Total Invested | $1.05B▲ 72.45% |
| Investors Holding | 248▲ 4.00% |
ESG Score
No data
About Xeris Pharmaceuticals Inc
CEO: paul Edick